Related Experiment Video
Updated: Jul 16, 2026
Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery
Published on: April 3, 2026
Selective mastectomy in the management of locally advanced breast cancer
Verity Ahern1, John Boyages, Val Gebski
1Department of Radiation Oncology, Westmead Hospital, NSW 2145, Sydney, Australia. verity.ahern@awahs.healthnsw.gov.au
Purpose:
To evaluate local control for patients with locally advanced noninflammatory breast cancer (LABC) managed by selective mastectomy.
Methods And Materials:
Between 1979 and 1996, 176 patients with LABC were prospectively managed by chemotherapy (CT)-irradiation (RT)-CT without routine mastectomy. All surviving patients were followed for a minimum of 5 years.
Results:
A total of 132 patients (75%) had a T4 tumor and 22 (12.5%) supraclavicular nodal disease. The clinical complete response rate was 91% (160/176), which included 13 patients who underwent mastectomy and 2 an iridium wire implant. The first site of failure was local for 43 patients (breast +/- axilla for 38); 27 of these patients underwent salvage mastectomy and 11 did not for an overall mastectomy rate of 23% (40/176). If all 176 patients had undergone routine mastectomy (136 extra mastectomies), 11 additional patients may have avoided an unsalvageable first local relapse. The others would have either have not had a local relapse or would have suffered local relapse after distant disease. No tumor or treatment related factor was found to predict local disease at death. Median disease-free and overall survival for all patients was 26 and 52 months, respectively.
Conclusions:
Selective mastectomy in LABC may not jeopardize local control or survival.
